Bristol’s Pfizer, AstraZeneca Deals Could Add Up To $2 Billion To R&D Budget

Bristol-Myers Squibb's partnerships with AstraZeneca and Pfizer to develop several late-stage compounds may provide the company with $2 billion to support its research and development initiatives, the firm said